Dear ,

In the current issue of the OncoWuXi Newsletter, we would like to share with you our drug resistant tumor models. Other interesting topics covered in this issue include update in HER2 targeted in vivo models.

OncoWuXi Newsletter will continue to keep you up-to-date with our recent progress in cancer research. As part of WuXi Research Service Division (RSD), our topnotch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.

Translational Oncology
Drug Resistant Tumor Models
(1)    ALK inhibitor (Crizotinib) resistant models
  • Mechanisms of Crizotinib resistance
  • Genetically engineered Ba/F3-EML4-ALK-WT, -L1196M, -C1156Y, -G1202R, and -G1202R/L1196M models, validated with Crizotinib, Ceritinib, Brigatinib, Alectinib, or Lorlatinib both in vitro and in vivo
  • Genetically engineered Ba/F3-CD74-ROS1-G2032R model, validated with TPX-0005 both in vitro and in vivo
  • Crizotinib induced resistant LU-01-0319R and LU-01-0582RC lung cancer PDX models

(2)    EGFR TKIs resistant models
  • Mechanisms of EGFR TKIs resistance
  • Genetically engineered Ba/F3-EGFR-Del19/T790M, -Del19/T790M/C797S, and -L858R/T790M/C797S models, validated with Erlotinib, Afatinib, Osimertinib, and Brigatinib in vivo
  • Genetically engineered NCI-H1975 (Del19/T790M/C797S) and PC-9 (Del19/T790M/C797S) models, validated with Osimertinib, Erlotinib, Brigatinib, or Gefitinib in vivo
  • Erlotinib induced resistant LU-01-0055R lung cancer PDX model
  • 9 PDX models derived from clinically acquired EGFR TKIs resistant patients, validated with Erlotinib, Gefitinib, Osimertinib, Afatinib, or Poziotinib in vivo

(3)    PARP inhibitor induced resistant models
  • Mechanisms of PARP inhibitor resistance
  • Olarparib induced resistant MDA-MB-436 breast cancer CDX model
  • BMN-673 induced resistant CAPAN-1 pancreatic cancer CDX model

(4)    Tamoxifen induced resistant MCF-7 breast cancer CDX model

(5)    Genetically engineered Ba/F3-CCDC6-RET WT, -V804M, and -V804L models, validated with Cabozantinib , Vandetanib, Lenvatinib, Sunitinib, Regorafenib and Pralsetinib in vitro

(6)    Genetically engineered Ba/F3-TRK fusion cell lines and in vivo models, validated with LOXO-101 and RXDX-101 both in vitro and in vivo

(7)    List of drug resistant tumor models under development

Targeted Oncology
HER2 Targeted In Vivo Models
  • HER2 biology
  • Summary of HER2 targeted agents

(2)      HER2 related CDX models
  • 21 HER2 overexpression cancer cell lines and characterization by in vitro assays
  • BT474, HCC1954 and MDA-MB-468 breast cancer, NCI-N87 gastric cancer, and SK-OV-3 ovarian cancer CDX models, validated with Trastuzumab, T-DM1, and Paclitaxel
  • NCI-N87-luc gastric cancer intracranial implantation model, validated with HER2 inhibitor

(3)      HER2 related PDX models
  • HER2 expression in 12 gastric cancer PDX models
  • IHC and FISH analysis data for HER2 targeted PDX models
  • ST-02-0077, ST-02-0079, ST-02-0103, and ST-02-0074 gastric cancer PDX models, validated with Trastuzumab and T-DM1
  • BR-05-0434 and BR-05-0452E breast cancer PDX models, validated with Herceptin

We sincerely appreciate your interest, time and support, and would like to hear your feedback so we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns.

Best regards,
WuXi AppTec OncoWuXi Team